PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Modafinil - Narcolepsy
PAD Profile : Modafinil - Narcolepsy Important
Keywords :
sleepiness, fatigue
Brand Names Include :
Provigil
Important Information :
Pregnancy safety warnings.
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
09 August 2023
Surrey Heartlands Medicines Safety Committee (MSC)
The MHRA published in the Drug Safety Update (Dec 2014, updated November 2020) an update on the safety of modafinil, in regard to its effect on unborn children. Modafinil potentially increases the risk of congenital malformations when used in pregnancy.
Modafinil should not be used during pregnancy and women of childbearing potential must use effective contraception during treatment and for 2 months after stopping modafinil.
See link to the MHRA information for further information https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/936767/Nov-2020-DSU-PDF-1.pdf
03 May 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
GENERIC Modafinil has been considered by the PCN and has been assigned a AMBER traffic light status
NOTE - the branded product, Provigil, was considered BLACK at the PCN in May 2017.
03 September 2014
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Modafinil is only licensed for narcolepsy (with or without cataplexy). Agreed as Amber (suitable for shared care). Shared Care Agreement under development. Modafinil for any other unlicensed indication was granted a RED traffic light status.
Associated BNF Codes
04. Central Nervous System
04.04.00. CNS stimulants and drugs used for ADHD